Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is a heterogenous disorder characterized by chronic ovulation dysfunction and hyperandrogenism. It is considered the most common endocrinological disorder, affecting up to 25% of women of reproductive age, and associated with long-term metabolic abnormalities predisposing to cardiovascular risk, such as insulin resistance (IR), dyslipidemia, endothelial dysfunction, and systemic inflammation. PCOS is also characterized by elevated serum levels of luteinizing hormone (LH), causing a condition of hyperandrogenism and a consequent altered ratio between LH and the follicle stimulating hormone (FSH). Over the years, several different approaches have been proposed to alleviate PCOS symptoms. Supplementation with natural molecules such as inositols, resveratrol, flavonoids and flavones, vitamin C, vitamin E and vitamin D, and omega-3 fatty acids may contribute to overcoming PCOS pathological features, including the presence of immature oocyte, IR, hyperandrogenism, oxidative stress and inflammation. This review provides a comprehensive overview of the current knowledge about the efficacy of natural molecule supplementation in the management of PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121 · cited 1×
“It is often characterized by a condition of chronic oligo—or anovulation (usually manifested as oligo—or amenorrhea), and hyperandrogenism [3], which derives from elevated serum levels of luteinizing hormone (LH) and a consequent altered ratio between LH and follicle stimulating hormone (FSH) [4–7].”
BackgroundDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 1×
“This metabolic alteration is an indicator for increased cardiovascular risk and for the development of other serious related diseases, including type 2 diabetes, hypertension, and metabolic syndrome [39].”
BackgroundChen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., Shacter, E., & Levine, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506390102 · Cited by 1,075 · cited 1×
“Notably, impairment of these functions may contribute to the development of ovarian cysts [67].”
BackgroundThe polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis
Wekker, V, van Dammen, L., Koning, A., Heida, K. Y., Painter, R. C., Limpens, J., Laven, J. S. E., Roeters van Lennep, J. E., Roseboom, T. J., & Hoek, A. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa029 · Cited by 425 · cited 2×
“Therefore, administration of omega-3 fatty acids should be specific only for PCOS women who already exhibit inflammatory and cardiovascular-related symptoms, which usually occur between 40 and 45 years of age [94,95].”
BackgroundVery long-chain n -3 fatty acids and human health: fact, fiction and the future
Calder, P. C. (2018) · Proceedings of the Nutrition Society · doi:10.1017/s0029665117003950 · Cited by 419
Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
Guastella, E., Longo, R. A., & Carmina, E. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.02.014 · Cited by 205
Oligoanovulation with Polycystic Ovaries But Not Overt Hyperandrogenism
Dewailly, D., Catteau-Jonard, S., Reyss, A.-C., Leroy, M., & Pigny, P. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1054 · Cited by 198
Polycystic ovary syndrome throughout a woman’s life
Group of interest in Reproductive Endocrinology (GIER) of the Spanish Fertility Society (SEF), Bellver, J., Rodríguez-Tabernero, L., Robles, A., Muñoz, E., Martínez, F., Landeras, J., García-Velasco, J., Fontes, J., Álvarez, M., et al. (2018) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-017-1047-7 · Cited by 180 · cited 2×
“Therefore, administration of omega-3 fatty acids should be specific only for PCOS women who already exhibit inflammatory and cardiovascular-related symptoms, which usually occur between 40 and 45 years of age [94,95].”
BackgroundZheng, J.-S., Huang, T., Yang, J., Fu, Y.-Q., & Li, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044525 · Cited by 126
Research works printed but not linked: 86
- Papaleo, 2007, Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction, Gynecol. Endocrinol., 23, 700, 10.1080/09513590701672405 · DOI · Paper page
- Barnard, 2007, Quality of life and psychological wellbeing in polycystic ovary syndrome, Hum. Reprod., 22, 2279, 10.1093/humrep/dem108 · DOI · Paper page
- Dunaif, 1997, Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis, Endocr. Rev., 18, 774
- Vauhkonen, 2000, Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome, Hum. Reprod., 15, 1266, 10.1093/humrep/15.6.1266 · DOI · Paper page
- Alexandraki, 2006, Inflammatory and endothelial markers in women with polycystic ovary syndrome, Eur. J. Clin. Investig., 36, 691, 10.1111/j.1365-2362.2006.01712.x · DOI · Paper page
- ESHRE, The Rotterdam, and ASRM-Sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod., 19, 41–47. · DOI · Paper page
- McLuskie, 2017, New diagnosis of polycystic ovary syndrome, BMJ, 12, 356:i6456
- Welt, 2006, Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: The impact of weight on phenotype and metabolic features, J. Clin. Endocrinol. Metab., 91, 4842, 10.1210/jc.2006-1327 · DOI · Paper page
- Pehlivanov, 2007, Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population, Gynecol. Endocrinol., 23, 604, 10.1080/09513590701536246 · DOI · Paper page
- Glinicki, 2012, Phenotype and metabolic disorders in polycystic ovary syndrome, ISRN Endocrinol., 2012, 569862
- Kar, 2013, Anthropometric, clinical, and metabolic comparisons of the four Rotterdam PCOS phenotypes: A prospective study of PCOS women, J. Hum. Reprod. Sci., 6, 194, 10.4103/0974-1208.121422 · DOI · Paper page
- Jamil, 2015, A case–control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria, Reprod. Health, 12, 7, 10.1186/1742-4755-12-7 · DOI · Paper page
- Nestler, 1997, Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications, Semin. Reprod. Endocrinol., 15, 111, 10.1055/s-2007-1016294 · DOI · Paper page
- Baillargeon, 2003, Insulin sensitizers for polycystic ovary syndrome, Clin. Obstet. Gynecol., 46, 325, 10.1097/00003081-200306000-00011 · DOI · Paper page
- Mayer, 2015, Polycystic ovary syndrome and insulin: Our understanding in the past, present and future, Womens Health, 11, 137
- Ciampelli, 1999, Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome, Metabolism, 48, 167, 10.1016/S0026-0495(99)90028-8 · DOI
- Genazzani, 2004, Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome, Fertil. Steril., 81, 114, 10.1016/j.fertnstert.2003.05.020 · DOI
- Holte, 1994, The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women, Clin. Endocrinol., 41, 473, 10.1111/j.1365-2265.1994.tb02578.x · DOI · Paper page
- Robinson, 1996, Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries, Clin. Endocrinol., 44, 277, 10.1046/j.1365-2265.1996.674495.x · DOI · Paper page
- Venkatesan, 2001, Insulin resistance in polycystic ovary syndrome: Progress and paradoxes, Recent Prog. Horm. Res., 56, 295, 10.1210/rp.56.1.295 · DOI · Paper page
- Dunaif, 2006, Insulin resistance in women with polycystic ovary syndrome, Fertil. Steril., 86, S13, 10.1016/j.fertnstert.2006.04.011 · DOI
- Jakimiuk, 2014, The role of inositol deficiency in the etiology of Polycystic ovary syndrome disorders, Ginekol. Pol., 85, 54, 10.17772/gp/1691 · DOI
- Daughaday, 1955, The synthesis of inositol in the immature rat ANC chick embryo, J. Biol. Chem., 212, 869, 10.1016/S0021-9258(18)71025-9 · DOI
- Garzon, 2018, Inositol in polycystic ovary syndrome: Restoring fertility through a pathophysiology-based approach, Trends Endocrinol. Metab., 29, 768, 10.1016/j.tem.2018.09.001 · DOI · Paper page
- Unfer, 2017, Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials, Endocr. Connect., 6, 647, 10.1530/EC-17-0243 · DOI · Paper page
- Monastra, 2018, Alpha-lactalbumin effect on myo-inositol intestinal absorption: In vivo and in vitro, Curr. Drug Deliv., 15, 1305, 10.2174/1567201815666180509102641 · DOI · Paper page
- Bevilacqua, 2015, Results from the international consensus conference on myo-inositol and d-chiro-inositol in obstetrics and gynecology-assisted reproduction technology, Gynecol. Endocrinol., 31, 441, 10.3109/09513590.2015.1006616 · DOI · Paper page
- Colazingari, 2013, The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: Results froma randomized controlled trial, Arch. Gynecol. Obstet., 288, 1405, 10.1007/s00404-013-2855-3 · DOI
- Ravanos, 2017, Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality?, Eur. Rev. Med. Pharmacol. Sci., 21, 5491
- Dinicola, 2014, The rationale of the myo-inositol and d-chiro-inositol combined treatment for polycystic ovary syndrome, J. Clin. Pharmacol., 54, 1079, 10.1002/jcph.362 · DOI · Paper page
- Bevilacqua, 2019, Myo-inositol and D-Chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model, J. Cell. Physiol., 234, 9387, 10.1002/jcp.27623 · DOI · Paper page
- Tabrizi, 2018, The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials, Lipids Health Dis., 17, 123, 10.1186/s12944-018-0779-4 · DOI
- Buonomo, 2018, Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women, J. Ovarian Res., 11, 38, 10.1186/s13048-018-0411-2 · DOI · Paper page
- Roseff, 2020, Inositol treatment for PCOS should be science-based and not arbitrary, Int. J. Endocrinol., 2020, 6461254, 10.1155/2020/6461254 · DOI · Paper page
- Liu, 2013, Resveratrol protects against age-associated infertility in mice, Hum. Reprod., 28, 707, 10.1093/humrep/des437 · DOI · Paper page
- Zhang, 2016, SIRT1, 2, 3 protect mouse oocytes from postovulatory aging, Aging, 8, 685, 10.18632/aging.100911 · DOI · Paper page
- Cabello, 2015, Effects of resveratrol on ovarian response to controlled ovarian hyperstimulation in ob/ob mice, Fertil. Steril., 103, 570, 10.1016/j.fertnstert.2014.10.034 · DOI
- Ortega, 2015, Ovarian actions of resveratrol, Ann. N. Y. Acad. Sci., 1348, 86, 10.1111/nyas.12875 · DOI
- Aquino, 2014, Complementary therapy in polycystic ovary syndrome, Transl. Med. UniSa, 9, 56
- Ochiai, 2019, Preconception resveratrol intake against infertility: Friend or foe?, Reprod. Med. Biol., 19, 107, 10.1002/rmb2.12303 · DOI
- Kuroda, 2020, The actions of resveratrol in decidualizing endometrium: Acceleration or inhibition?, Biol. Reprod., 103, 1152, 10.1093/biolre/ioaa172 · DOI
- Ochiai, 2019, Influence of resveratrol supplementation on ivf–embryo transfer cycle outcome, Reprod. Biomed. Online, 39, 205, 10.1016/j.rbmo.2019.03.205 · DOI
- Ochiai, 2019, Resveratrol inhibits decidualization by accelerating downregulation of the CRABP2-RAR pathway in differentiating human endometrial stromal cells, Cell Death Dis., 10, 276, 10.1038/s41419-019-1511-7 · DOI
- Benrick, 2013, resveratrol is not as effective as physical exercise for improving reproductive and metabolic functions in rats with dihydrotestosterone-induced polycystic ovary syndrome, Evid. Based Complement Altern. Med., 2013, 964070, 10.1155/2013/964070 · DOI
- Manna, 2000, Resveratrol sup- presses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: Potential role of re- active oxygen intermediates and lipid peroxidation, J. Immunol., 164, 6509, 10.4049/jimmunol.164.12.6509 · DOI · Paper page
- Aggarwal, 2004, Suppression of the nuclear factor-κB activation pathway by spice-derived phytochemicals: Reasoning for seasoning, Ann. N. Y. Acad. Sci., 1030, 434, 10.1196/annals.1329.054 · DOI · Paper page
- Csaki, 2008, Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro, Biochem. Pharmacol., 75, 677, 10.1016/j.bcp.2007.09.014 · DOI · Paper page
- Shakibaei, 2007, Resveratrol in-hibits IL-1β–induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro, Ann. N. Y. Acad. Sci., 1095, 554, 10.1196/annals.1397.060 · DOI · Paper page
- Kiran, 2017, Flavonoid: A review on Naringenin, J. Pharmacol. Phytochem., 6, 2778
- Ho, 1998, Improved high-performance liquid chromatographic method for the analysis of Naringenin grapefruit juice without extraction, Pharm. Pharmacol. Commun., 4, 473
- Frabasile, 2017, The citrus flavanone naringenin impairs dengue virus replication in human cells, Sci. Rep., 7, 41864, 10.1038/srep41864 · DOI
- Kicinska, A., Kampa, R.P., Daniluk, J., Sek, A., Jarmuszkiewicz, W., Szewczyk, A., and Bednarczyk, P. (2020). Regulation of the mitochondrial bk ca channel by the citrus flavonoid naringenin as a potential means of preventing cell damage. Molecules, 25. · doi:10.3390/molecules25133010
- Wawrzkiewicz-Jałowiecka, A., Kowalczyk, K., Trybek, P., Jarosz, T., Radosz, P., Setlak, M., and Madej, P. (2020). In search of new therapeutics-molecular aspects of the PCOS pathophysiology: Genetics, hormones, metabolism and beyond. Int. J. Mol. Sci., 21. · DOI
- Hong, 2019, The flavanone, naringenin, modifies an-tioxidant and steroidogenic enzyme activity in a rat model of letrozole-induced poly-cystic ovary syndrome, Med. Sci. Monit., 25, 395, 10.12659/MSM.912341 · DOI
- Yuan, 2017, Rutin ameliorates obesity through brown fat activation, FASEB J., 31, 333, 10.1096/fj.201600459rr · DOI · Paper page
- Hu, 2017, Brown adipose tissue activation by rutin ameliorates polycystic ovary syndrome in rat, J. Nutr. Biochem., 47, 21, 10.1016/j.jnutbio.2017.04.012 · DOI
- Olaniyan, 2019, Vitamin C suppresses ovarian pathophysiology in experimental polycystic ovarian syndrome, Pathophysiology, 26, 331, 10.1016/j.pathophys.2019.08.003 · DOI
- Bendich, 1986, The antioxidant role of vitamin C, Adv. Free Radic. Biol. Med., 2, 419, 10.1016/S8755-9668(86)80021-7 · DOI · Paper page
- Palamanda, 1993, Involvement of vitamin e and protein thiols in the inhibition of microsomal lipid peroxidation by glutathione, Lipids, 28, 427, 10.1007/BF02535941 · DOI
- Cicek, 2012, Vitamin E effect on controlled ovarian stimulation of unexplained infertile women, J. Assist. Reprod. Genet., 29, 325, 10.1007/s10815-012-9714-1 · DOI
- Izadi, 2019, Hormonal and metabolic effects of coenzyme q10 and/ or vitamin E in patients with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 104, 319
- Chen, J., Guo, Q., Pei, Y.H., Ren, Q.-L., Chi, L., Hu, R.K.H., and Tan, Y. (2020). Effect of a short-term vitamin E supplementation on oxidative stress in infertile PCOS women under ovulation induction: A retrospective cohort study. BMC Womens Health, 20. · DOI
- Monastra, 2018, Vitamin D: A steroid hormone with progesterone-like activity, Eur. Rev. Med. Pharmacol. Sci., 22, 2502
- Holick, 2007, Vitamin D deficiency, N. Engl. J. Med., 357, 266, 10.1056/NEJMra070553 · DOI · Paper page
- Li, 2011, Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome, Metabolism, 60, 1475, 10.1016/j.metabol.2011.03.002 · DOI · Paper page
- Wehr, 2009, Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome, Eur. J. Endocrinol., 161, 575, 10.1530/EJE-09-0432 · DOI · Paper page
- Snackey, 2013, The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: A systematic review, Eur. J. Endocrinol., 169, 853, 10.1530/EJE-13-0617 · DOI · Paper page
- Lerchbaum, 2012, Vitamin D and fertility: A systematic review, Eur. J. Endocrinol., 166, 765, 10.1530/EJE-11-0984 · DOI · Paper page
- Kadoura, 2019, Effect of calcium and vitamin d supplements as an adjuvant therapy to metformin on menstrual cycle abnormalities, hormonal profile, and IGF-1 system in polycystic ovary syndrome patients: A randomized, placebo-controlled clinical trial, Adv. Pharmacol. Sci., 2019, 9680390
- Miao, 2020, Effect of vitamin D supplementation on polycystic ovary syndrome: A meta-analysis, Exp. Ther. Med., 19, 2641
- Trummer, 2019, Effects of vitamin D supplementation on metabolic and endocrine parameters in PCOS: A randomized-controlled trial, Eur. J. Nutr., 58, 2019, 10.1007/s00394-018-1760-8 · DOI · Paper page
- Lerchbaum, 2014, Vitamin D and female fertility, Curr. Opin. Obstet. Gynecol., 26, 145, 10.1097/GCO.0000000000000065 · DOI · Paper page
- Merhi, 2019, Crosstalk between advanced glycation end products and vitamin D: A compelling paradigm for the treatment of ovarian dysfunction in PCOS, Mol. Cell. Endocrinol., 479, 20, 10.1016/j.mce.2018.08.010 · DOI
- Merhi, 2018, Advanced glycation end products alter steroidogenic gene expression by granulosa cells: An effect partially reversible by vitamin D, Mol. Hum. Reprod., 24, 318, 10.1093/molehr/gay014 · DOI
- Forouhi, 2015, Effect of omega-3 fatty acids supplementation on testosterone levels in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials, J. Nutr. Sci. Diet., 1, 165
- Oner, 2013, Efficacy of omega-3 in the treatment of polycystic ovary syndrome, J. Obstet. Gynaecol., 33, 289, 10.3109/01443615.2012.751365 · DOI · Paper page
- Monk, 2014, n-3 polyunsaturated fatty acids and mechanisms to mitigate inflammatory paracrine signaling in obesity-associated breast cancer, Nutrients, 6, 4760, 10.3390/nu6114760 · DOI
- Calder, 2013, Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology?, Br. J. Clin. Pharmacol., 75, 645, 10.1111/j.1365-2125.2012.04374.x · DOI · Paper page
- Poudyal, 2011, Omega-3 fatty acids and metabolic syndrome: Effects and emerging mechanisms of action, Prog. Lipid Res., 50, 372, 10.1016/j.plipres.2011.06.003 · DOI · Paper page
- Simopoulos, 2002, The importance of the ratio of omega-6/omega-3 essential fatty acids, Biomed. Pharmacother., 56, 365, 10.1016/S0753-3322(02)00253-6 · DOI · Paper page
- Martorell, 2018, Resolvins as proresolving inflammatory mediators in cardiovascular disease, Eur. J. Med. Chem., 153, 123, 10.1016/j.ejmech.2017.07.018 · DOI
- Sima, 2016, Therapeutic targets for management of periodontitis and diabetes, Curr. Pharm. Des., 22, 2216, 10.2174/1381612822666160216150338 · DOI
- Sadeghi, 2017, Effect of omega-3 fatty acids supplementation on insulin resistance in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials, Diabetes Metab. Syndr., 11, 157, 10.1016/j.dsx.2016.06.025 · DOI
- Khani, 2017, Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome, J. Res. Med. Sci., 22, 64, 10.4103/jrms.JRMS_644_16 · DOI · Paper page
- Harris, 1990, The combined effects of N-3 fatty acids and aspirin on hemostatic parameters in man, Thromb. Res., 57, 517, 10.1016/0049-3848(90)90069-O · DOI
- Warstedt, 2009, The Effects of Omega-3 Fatty Acid Supplementation in Pregnancy on Maternal Eicosanoid, Cytokine, and Chemokine Secretion, Pediatric Res., 66, 212, 10.1203/PDR.0b013e3181aabd1c · DOI
Cited by
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
Xing, C., Zhao, H., Zhang, J., & He, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.945609 · Cited by 82
Role of Omega-3 Fatty Acids in Improving Metabolic Dysfunctions in Polycystic Ovary Syndrome
Albardan, L., Platat, C., & Kalupahana, N. S. (2024) · Nutrients · doi:10.3390/nu16172961 · Cited by 18
“Potential benefits of dietary supplements in the management of PCOS have been previously reviewed by Iervolino et al. [54] and Alesi et al. [18].”
BackgroundPolycystic Ovary Syndrome (PCOS): From Diagnosis to Treatment
Rani, R., Priyanka, P., Yadav, R., Bajal, N., Mandal, B. S., & Kumar, A. (2024) · International Journal of Environment, Agriculture and Biotechnology · doi:10.22161/ijeab.94.5 · Cited by 4
Metadata
- Authors
- Iervolino, M., Lepore, E., Forte, G., Laganà, A. S., Buzzaccarini, G., & Unfer, V.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2021-05-15
- Volume
- 13
- Issue
- 5
- Pages
- 1677
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W3160583309
- Cited by
- 98
- References
- 15
- FWCI
- 12.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review. https://app.cochat.ai/papers/10.3390/nu13051677
- The paper
- Iervolino, M., Lepore, E., Forte, G., Laganà, A. S., Buzzaccarini, G., & Unfer, V. (2021). Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review. Nutrients. https://doi.org/10.3390/nu13051677
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.